Overview

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab
Erlotinib Hydrochloride